PEPG News

NEW YORK--(BUSINESS WIRE)---- $PEPG #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has rec

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. “This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1. With class-leading mean mis-

LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or “the Company”) (NASDAQ: PEPG) and certain of its officers.

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (PepGen or the Company) (NASDAQ: PEPG) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York,...

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

NEW YORK--(BUSINESS WIRE)---- $PEPG #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has rec

LOS ANGELES--(BUSINESS WIRE)--PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of PepGen Inc. (NASDAQ: PEPG) securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). PepGen is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating t

PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.

PepGen shares are trading higher by 90% during Monday's session. The company announced early data from its FREEDOM-DM1 trial for myotonic dystrophy.